BENGALURU – The trial demonstrated exceptional potential for TBA-7371 in combating TB, indicating robust bactericidal activity with just 14 days of treatment among patients with drug-susceptible pulmonary tuberculosis. Notably, the compound was well-tolerated, displaying significant dose-dependent efficacy, marking a pivotal leap forward in TB therapeutics.
FNDR, a prominent not-for-profit biotech R&D organization, spearheads the quest for pioneering therapeutics, diagnostics, and devices targeting diseases with profound socio-economic impacts. Since its establishment in 2014, FNDR has curated a diverse therapeutic portfolio spanning diseases like TB, malaria, dengue, COVID-19, and others, encompassing early-stage discovery to advanced clinical trials.
Read More
- ADHD: An emerging discussion on a shared disorder
- Matcha Mania: Is the green drink really as healthy as it seems?
- Oman marks World Health Day, highlights commitment to health innovation and digital transformation
- Muscat oncology conference showcases latest advances in immunotherapy and targeted therapy
- Oman health authorities urge people to break fast if serious symptoms appear
